Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors

Purpose: The endothelin axis and the endothelin A (ETA) receptor have been implicated in tumor development and bone metastasis. This study aimed to investigate the pharmacokinetic (PK) and safety profiles of the specific ETA receptor antagonist, zibotentan, in elderly, male Chinese patients with advanced solid tumors. The PK data generated in these Chinese patients were further compared with those previously reported in Japanese and Caucasian patient populations. Methods: In this Phase I, open‐label study, patients received a single dose of zibotentan 10 mg on Day 1, followed by a 72‐h washout period and 12 consecutive days of once‐daily zibotentan 10 mg. Results: Fifteen patients received at least one dose of zibotentan 10 mg. Exposure was demonstrated in all patients and the PK profiles following single dosing and multiple dosing showed relatively rapid absorption, decline in a monophasic manner, a modest amount of accumulation, and relatively low apparent clearance and volume of distribution. Zibotentan was well tolerated with no new safety concerns. Adverse events reported in >1 patient were pyrexia (n = 4), constipation (n = 3), headache (n = 3) and peripheral edema (n = 2). Comparative analysis found no evidence of significant differences in zibotentan exposure between the Chinese patients in our study, and the previous Japanese and Caucasian studies. Conclusions: The PK and safety profiles of zibotentan determined in this Chinese patient population are similar to those previously reported. Our findings suggest no clinically relevant inter‐ethnic differences in zibotentan disposition between the patient populations analyzed. 2012 Springer‐Verlag.